Skip to main content

Advertisement

Table 1 Dosage, duration, outcome, and toxicity of intravenous colistimethate sodium in critically ill patients

From: Renal and neurological side effects of colistin in critically ill patients

Author Patients (N) APACHE II (mean ± SD) CMS dose/duration [mean ± SD or median (range)] Clinical cure N (%) Nephrotoxicity N (%) Neurotoxicity
Levin 59 (60 infections) 13.1 ± 7 152.8 mg ± 62.8 mg 12.6 ± 6.8 days 35 (58.3) 22 (37) none
Markou 24 (26 infections) 20.6 (mean) 3 MIUq8h 13.5 days (4-24 days) 17 (65.4) 3 (14.5) none
Garnacho- Montero 21 19.6 ± 7.2 2.5 mg-5 mg/kg/day 14.7 ± 4.1days 12 (57.1) 5 (24) none
Michalopoulos 43 25.8 ± 7.7 3 MIUq8h 18.6 ± 5.8 days 32 (74) 8 (18.6) none
Falagas 17 (19 infections) 14 (median) 43.4 ± 14.6 days 4.4 MIU ± 2.1 MIU 14 (74) 1 (5.2) 1
Kasiakou 50 (54 infections) 16.1 ± 6.1 4.5 MIU ± 2.3 MIU 21.3 ± 16 days 36 (66.7) 4 (8) 1a
Reina 55 21 ± 7 5 mg/kg (max 300 mg/day) 13 ± 5 days NA 0 (0) none
Petrosillob 14 NA 2 MIUq8h 12 days (mean) 9 (64) 1 (7.1) none
Kallel 75 (78 infections) NA (SAPS II 37 ± 14)   5.5 MIU ± 1.1 MIU 9.3 ± 3.8 days 60 (76.9) 7/52 (13.5) 1
Koomanachai 78 21.9 (mean) 179.6 mg/day (mean) 11.9 days (mean) 63 (80.8) 24 (30.8) none
Betrosian 15 14 ± 2 5.83 MIU ± 2.3 MIU duration NA 9 (60) 5 (33) none
Bassettib 29 17 ± 3.7 2 MIUq8h 17.7 ± 10.4 days 22 (76) 3 (10) none
Kallel 60 NA (SAPS II 35 ± 12) 2 MIUq8h 9.5 ± 3.8 days 45 (75) 0 (0) NA
Falagas 21 19 ± 4 5.5 MIU ± 1.9 MIU 17.7 ± 11.7 days 11 (52.4) 3 (14.3) none
Falagas 14 (CMS mono) 14.3 ± 7.4 4.6 MIU ± 2.3 MIU 14.2 ± 7.3 days 12 (85.7) 0 (0) NA
  57 (CMS+MERO) 15.4 ± 6.6 5.5 MIU ± 2.2 MIU 17.8 ± 11.4 days 39 (68.4) 4 (7) NA
Pintado 60 11.2 ± 7.7 4.42 MIU ± 1.39 MIU 20 ± 9.2 days 43 (71.7) 6/55 (10.9) none
Sabuda 12 NA 3.7 mg/kg 14.7 ± 13.8 days 8 (66.7) 5 (41.6) 4 cases
Huang 15 14.7 ± 4.5 1.28 MIU ± 0.25 MIU 22.3 ± 6.2 days 11 (73.3) 0 (0) none
Hartzell 66 8.3 ± 6.5 4.3 ± 1.2 mg/kg/day 15.8 ± 9.2 days NA 30 (45) 2 cases
Kim 42 (47 infections) NA 2.25 g (0.6-8.7g)c 16.6 ± 14.8 dayse 10/15 (66)d 15 (31.9) none
Kwon 71 NA 4.6 mg/kg (median) 13 days (7-22 days) NA 38 (53.5) none
Cheng 115f 6 (median) dose NA 12 ± 7daysg 59 (51) 12/84 (14) 4 cases
Song 10 NA 150 mg q12h 8.1 ± 1.8 days 7 (70) 0 (0) none
Falagash 258 17 (range 2-39) up to 3 MIUq8h mean 17.9 days (10-22) 204 (79.1) 26 (10) NA
Kofteridis 43 17.7 ±7.6 3 MIUq8h median 10 days (4-36 days) 14 (32.5) 8 (19) none
DeRyke 30 13 (range 7-18)i 5.1 ± 2 mg/kg/dayj median 8 days (3-24) NA 10 (33%) none
  1. NA = not available; APACHE II = Acute Physiology and Chronic Health Evaluation II score; SAPS 2 = Simplified Acute Physiology Score 2; MIU = million International Units; CMS = colistimethate sodium; MERO = meropenem.
  2. aSame patient as in reference 6; b+ rifampicine; cmean cumulative CMS dose when nephrotoxicity occurred; din patients presenting nephrotoxicity; ein patients presenting nephrotoxicity (vs. 9.5 ± 5.6 days in patients without nephrotoxicity, p = 0.07); f31 patients on renal replacement therapy at start of CMS treatment; gin patients with good clinical response (vs. 11 ± 11 days in patients with poor response); hincludes data on 108 patients from references 5, 7, and 16; iin patients who developed nephrotoxicity; jbased on ideal body weight.